DevvStream Holdings Inc. and BioVie Inc. Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
DevvStream Holdings Inc. and BioVie Inc. Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 10, 2023 / RedChip Companies will air interviews with DevvStream Holdings Inc. (CBOE:DESG)(OTCQB:DSTRF)(FSE:CQ0) and BioVie Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money Show, a sponsored program on Bloomberg TV, this Saturday, November 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛罗里达州奥兰多/ACCESSWIRE /2023 年 11 月 10 日/ 红筹公司将于美国东部时间11月11日星期六晚上7点在彭博电视台的赞助节目《红筹小股大钱秀》上播出对DevvStream Holdings Inc.（芝加哥期权交易所代码：DESG）（场外交易所代码：DSTRF）（FSE: CQ0）和BioVie Inc.（纳斯达克股票代码：BIVI）的采访。据估计，美国有7300万个家庭可以收看彭博电视台。
Access the interviews in their entirety at:
访问访谈的全部内容，请访问：
- DevvStream:
- BioVie:
- devvStream：
- BioVie：
Sunny Trinh, CEO, of DevvStream appears on the RedChip Small Stocks Big Money Show on Bloomberg TV to provide a corporate update. Founded in 2021, DevvStream is a technology-based sustainability company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. DevvStream works with governments and corporations worldwide to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air-creating carbon credits in the process.
DevvStream首席执行官Sunny Trinh出现在彭博电视台的RedChip Small Stocks Big Money Show上，提供公司最新消息。DevvStream成立于2021年，是一家以科技为基础的可持续发展公司，致力于推动环境资产的开发和货币化，最初的重点是碳市场。DevvStream与全球政府和企业合作，通过实施精心策划的绿色技术项目来实现其可持续发展目标，这些项目可产生可再生能源，提高能源效率，消除或减少排放，并在此过程中直接从产生空气的碳信用额中封存碳。
Also appearing on the RedChip Small Stocks Big Money Show this week is Cuong Do, President and CEO of BioVie. BioVie is poised for significant catalysts in 2023, including top-line data read out from its Alzheimer's Phase 3 trial, expected in Q4 2023. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate.
BioVie总裁兼首席执行官Cuong Do也出现在本周的RedChip Small Stocks Big Money Show上。BioVie有望在2023年推出重要的催化剂，包括预计于2023年第四季度推出的阿尔茨海默氏症3期试验的顶级数据。BioVie正在进行其他多项工作，这些举措可能会产生额外的催化剂，并将在公司认为适当时公开发布。
About DevvStream Holdings Inc.
关于 DevvStream 控股有限公司
DevvStream is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. DevvStream works with governments and corporations worldwide to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air. DevvStream also helps these organizations meet their net zero goals by providing them access to high-quality carbon credits.
DevvStream是一家以科技为基础的ESG公司，致力于推进环境资产的开发和货币化，最初的重点是碳市场。DevvStream与全球政府和企业合作，通过实施精心策划的绿色技术项目来实现其可持续发展目标，这些项目可以产生可再生能源，提高能源效率，消除或减少排放，并直接从空气中封存碳。DevvStream 还通过为这些组织提供获得高质量碳信用额度的机会，帮助他们实现净零目标。
About BioVie
关于 BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit
BioVie Inc.（纳斯达克股票代码：BIVI）是一家临床阶段的公司，开发用于治疗神经系统和神经退行性疾病以及晚期肝病的创新药物疗法。在神经退行性疾病中，该公司的候选药物 NE3107 抑制导致神经炎症和胰岛素抵抗的 ERK 和 nfKB 的炎症激活（例如 TNF 信号传导），但不能抑制其稳态功能（例如胰岛素信号传导和神经元生长与存活）。两者都是阿尔茨海默氏症和帕金森氏病的驱动因素。该公司正在进行一项可能至关重要的3期随机、双盲、安慰剂对照、平行组、多中心研究，以评估轻度至中度阿尔茨海默氏病（NCT04669028）患者的 NE3107。在2022年12月的阿尔茨海默病临床试验（CTAD）年会上，公布了一项2期研究者启动的试验（NCT05227820）的结果，显示接受Ne3107治疗的患者的认知和生物标志物水平得到改善。估计有600万美国人患有阿尔茨海默氏症。一项针对帕金森氏病 NE3107（NCT05083260）的2期研究已经完成，2023年3月在瑞典哥德堡举行的阿尔茨海默氏症和帕金森氏病及相关神经系统疾病国际会议上公布的数据显示，与单独接受左旋多巴治疗的患者相比，使用 NE3107 和左旋多巴联合治疗的患者，“早上” 症状得到显著改善，运动控制也具有临床意义，没有与药物相关的不良事件。在肝病方面，该公司具有美国食品药品管理局快速通道资格的候选孤儿药 BIV201（连续输注特利加压素）正在接受美国食品药品管理局关于治疗慢性肝硬化腹水的 BIV201 3期临床试验设计的指导意见的评估和讨论。该活性药物已在美国和大约40个国家获准用于晚期肝硬化的相关并发症。欲了解更多信息，请访问
About RedChip Companies
关于红筹公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家Inc. 5000公司，是一家专注于微型股和小型股公司的国际投资者关系、媒体和研究公司。30年来，RedChip为其客户提供了具体、可衡量的结果。我们的时事通讯《RedChip Small Stocks Big Money Show》每周在线向6万名投资者发布。RedChip为微型股和小型股公司开发了业内最全面的服务平台。这些服务包括：股票研究的全球分销网络；美国主要城市的零售和机构路演；股票经纪商、区域投资协议、机构和家族办公室的境外营销；产生数百万独特投资者观点的数字媒体投资者关系平台；投资者网络研讨会和群组电话会议；每周在美国彭博社播出的电视节目 “红筹小股大额资金秀”；本地和全国市场的电视广告；公司产品和视频；网站设计；以及传统投资者关系服务，包括撰写新闻稿、撰写投资者简报、撰写季度电话会议剧本、战略咨询、融资等。
To learn more about RedChip's products and services, please visit:
要了解有关RedChip产品和服务的更多信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“今天发现明天的蓝筹股”
Follow RedChip on LinkedIn:
Follow RedChip on Facebook:
Follow RedChip on Instagram:
Follow RedChip on Twitter:
Follow RedChip on YouTube:
Follow RedChip on Rumble:
在领英上关注 RedChip：
在脸书上关注 RedChip：
在 Instagram 上关注 RedChip
在推特上关注 RedChip：
在 YouTube 上关注 RedChip
在 Rumble 上关注 RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系人：
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
戴夫·金特里
RedChip Companies
1-800-RED-CHIP (733-2447)
或 407-491-4498
info@redchip.com
SOURCE: RedChip
来源： redChip